Retacagri Blend

GLP-1 / Next-Gen

An experimental next-generation protocol combining triple agonist and amylin pathways for maximum metabolic effect.

💰 Compare Prices ← Back to Dictionary

Half-life

~5–7 days each

Research dose

Research titration protocols

Frequency

Once weekly

Routes

SubQ injection

How it works

Combines Retatrutide (GLP-1/GIP/Glucagon triple agonist) with Cagrilintide (amylin analogue). Retatrutide drives appetite suppression, GIP-mediated insulin enhancement, and glucagon-driven energy expenditure. Cagrilintide adds amylin-receptor-mediated satiety and gastric slowing. Four complementary pathways (GLP-1, GIP, Glucagon, Amylin) are engaged simultaneously.

Research uses

Advanced weight loss research

Multi-pathway metabolic studies

Next-generation obesity protocols

GLP-1 resistance models

Metabolic syndrome research

Research notes

This combination represents the leading edge of metabolic peptide research, combining a triple agonist with an amylin analogue to engage four distinct metabolic pathways simultaneously. Clinical trial data for this specific combination is limited but each component has Phase 2/3 data.

Analogous to the CagriSema concept (semaglutide + cagrilintide) but substituting retatrutide for semaglutide to add glucagon and GIP activity. The theoretical weight loss potential exceeds any currently approved therapeutic.

Storage

❄️Freeze lyophilized powder

🌡️Refrigerate once reconstituted

📅Use within 4 weeks

Ready to compare Retacagri Blend prices?

Real-time prices across 14 vendors with discount codes already applied.

Compare Prices →

Also in the dictionary